Display options
Cite
Zirjacks L, Stransky N, Klumpp L, et al. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules. 2021;11(11)doi: 10.3390/biom11111561.
Zirjacks, L., Stransky, N., Klumpp, L., Prause, L., Eckert, F., Zips, D., Schleicher, S., Handgretinger, R., Huber, S. M., & Ganser, K. (2021). Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules, 11(11), . https://doi.org/10.3390/biom11111561
Zirjacks, Lisa, et al. "Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study." Biomolecules vol. 11,11 (2021). doi: https://doi.org/10.3390/biom11111561
Zirjacks L, Stransky N, Klumpp L, Prause L, Eckert F, Zips D, Schleicher S, Handgretinger R, Huber SM, Ganser K. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules. 2021 Oct 21;11(11). doi: 10.3390/biom11111561. PMID: 34827559; PMCID: PMC8615869.
Copy Download .nbib Format: NLM
Share it on

Biomolecules. 2021 Oct 21;11(11). doi: 10.3390/biom11111561.

Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.

Biomolecules

Lisa Zirjacks, Nicolai Stransky, Lukas Klumpp, Lukas Prause, Franziska Eckert, Daniel Zips, Sabine Schleicher, Rupert Handgretinger, Stephan M Huber, Katrin Ganser

Affiliations

  1. Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.
  2. Department of Hematology and Oncology, University Hospital Tuebingen, Children's Hospital, 72076 Tuebingen, Germany.

PMID: 34827559 PMCID: PMC8615869 DOI: 10.3390/biom11111561

Abstract

Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder. Reportedly, DSF in combination with Cu

Keywords: MGMT promoter methylation; Nicoletti staining; brain tumor; primary spheroid culture; propidium iodide; radioresistance; survival fraction; tumor-initiating cells

References

  1. Genom Data. 2015 Sep 1;5:333-336 - PubMed
  2. Nat Cell Biol. 2018 Oct;20(10):1203-1214 - PubMed
  3. Curr Mol Pharmacol. 2012 Jan;5(1):102-14 - PubMed
  4. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  5. Cells. 2021 Feb 28;10(3): - PubMed
  6. Am J Psychiatry. 1982 Dec;139(12):1596-8 - PubMed
  7. Prostate Cancer Prostatic Dis. 2013 Dec;16(4):357-61 - PubMed
  8. Eur J Cancer Prev. 2014 May;23(3):225-32 - PubMed
  9. Am J Cancer Res. 2019 Nov 01;9(11):2442-2455 - PubMed
  10. J Neurol Sci. 2011 Apr 15;303(1-2):95-9 - PubMed
  11. Mol Cancer Ther. 2004 Sep;3(9):1049-60 - PubMed
  12. Oncotarget. 2012 Oct;3(10):1112-23 - PubMed
  13. J Neurooncol. 2019 May;142(3):537-544 - PubMed
  14. Trends Cell Biol. 2019 Mar;29(3):212-226 - PubMed
  15. Biochim Biophys Acta. 2012 Sep;1823(9):1580-93 - PubMed
  16. Clin Cancer Res. 2016 Aug 1;22(15):3860-75 - PubMed
  17. Sci Rep. 2018 Apr 3;8(1):5527 - PubMed
  18. F1000Res. 2018 Nov 15;7:1797 - PubMed
  19. PLoS One. 2013 Oct 23;8(10):e78130 - PubMed
  20. Drug Metab Dispos. 2021 Jun;49(6):434-441 - PubMed
  21. Biochem Biophys Res Commun. 2014 Apr 18;446(4):1010-6 - PubMed
  22. Cancer Cell. 2017 Jul 10;32(1):42-56.e6 - PubMed
  23. Nat Med. 2017 Oct 6;23(10):1124-1134 - PubMed
  24. Cancer Res Treat. 2019 Apr;51(2):696-705 - PubMed
  25. Front Oncol. 2015 Dec 07;5:275 - PubMed
  26. J Cell Mol Med. 2018 Jan;22(1):439-451 - PubMed
  27. Sci Rep. 2020 Mar 30;10(1):5686 - PubMed
  28. Neuro Oncol. 2017 Aug 1;19(8):1079-1087 - PubMed
  29. J Nucleic Acids. 2010 Nov 21;2010:543531 - PubMed
  30. Life Sci. 1991;48(3):291-9 - PubMed
  31. Arch Med Res. 2012 Apr;43(3):243-7 - PubMed
  32. Curr Neuropharmacol. 2018;16(5):627-635 - PubMed
  33. Cancer Chemother Pharmacol. 2021 Feb;87(2):159-172 - PubMed
  34. Mol Med Rep. 2015 Aug;12(2):2313-22 - PubMed
  35. Mol Cancer Res. 2013 Dec;11(12):1611-23 - PubMed
  36. J Neurooncol. 2018 May;138(1):105-111 - PubMed
  37. Onco Targets Ther. 2020 Oct 20;13:10631-10640 - PubMed
  38. Cancer Res. 2006 Nov 1;66(21):10425-33 - PubMed
  39. Lancet Oncol. 2009 May;10(5):459-66 - PubMed
  40. Int J Pharm. 2021 Mar 15;597:120250 - PubMed
  41. Oncotarget. 2012 Oct;3(10):1124-36 - PubMed
  42. Chem Res Toxicol. 1997 Dec;10(12):1319-24 - PubMed
  43. Arch Biochem Biophys. 2017 Nov 1;633:23-28 - PubMed
  44. J Med Chem. 2004 Dec 30;47(27):6914-20 - PubMed
  45. Daru. 2019 Dec;27(2):853-862 - PubMed
  46. Neuro Oncol. 2021 Feb 25;23(2):240-250 - PubMed
  47. J Nucl Med. 2014 May;55(5):845-51 - PubMed
  48. Biochem Pharmacol. 1986 Oct 1;35(19):3341-7 - PubMed
  49. Cancer Cell. 2013 Sep 9;24(3):331-46 - PubMed
  50. Br J Cancer. 2012 Oct 23;107(9):1488-97 - PubMed
  51. Neuropharmacology. 1983 Sep;22(9):1159-63 - PubMed
  52. J Pharmacol Exp Ther. 1993 Jul;266(1):23-32 - PubMed
  53. Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9 - PubMed
  54. DNA Repair (Amst). 2004 Nov 2;3(11):1389-407 - PubMed
  55. Carcinogenesis. 2014 Mar;35(3):692-702 - PubMed
  56. Cancer Res. 2014 Oct 15;74(20):5819-31 - PubMed
  57. Int J Pharm. 2015 Oct 15;494(1):73-82 - PubMed
  58. Cell Commun Signal. 2020 Mar 5;18(1):36 - PubMed
  59. Biochem Pharmacol. 2000 Oct 1;60(7):947-53 - PubMed
  60. Clin Pharmacol Ther. 1984 Oct;36(4):520-6 - PubMed
  61. Mol Carcinog. 2016 Nov;55(11):1843-1857 - PubMed
  62. Acta Biomater. 2018 Mar 1;68:113-124 - PubMed
  63. Cancers (Basel). 2020 Nov 27;12(12): - PubMed
  64. J Toxicol Clin Toxicol. 1999;37(2):217-30 - PubMed
  65. Cancer Lett. 2015 Dec 1;369(1):86-96 - PubMed
  66. Int J Radiat Biol. 2007 May;83(5):319-29 - PubMed
  67. Cancer Cell. 2006 Mar;9(3):157-73 - PubMed
  68. Neuro Oncol. 2010 Jan;12(1):49-57 - PubMed
  69. Biochem Pharmacol. 2020 Dec;182:114267 - PubMed
  70. J Am Chem Soc. 2011 Aug 10;133(31):12229-37 - PubMed
  71. Neuro Oncol. 2015 Jun;17(6):810-21 - PubMed
  72. Cells. 2019 Sep 13;8(9): - PubMed
  73. Front Immunol. 2019 Mar 12;10:407 - PubMed

Publication Types

Grant support